Honored to be promoted to Professor of Medicine at @MayoClinic. Grateful for the support and belief from friends, colleagues, mentors, teachers and so so many people. Thankful for my family for their continued love and encouragement, allowing me to pursue my career!

FOR THE FIRST TIME IN 53 YEARS, THE KNICKS ARE NBA CHAMPIONS 🏆 New York defeats San Antonio 4-1 in the NBA Finals, capturing their third championship in franchise history!

The wait is over. @Arsenal are Premier League champions.

I look forward to this very important presentation in #EHA2026 about value of transplant in TP53 mutated #MDSsm and #AMLsm. The results clearly indicate a tail at end of curve and around 20% 23-year OS even among biallelic TP53mut patients, and especially in those with lower blast counts. Do NOT deprive patients from the opportunity of transplant without a very well-informed discussion! Patients with KPS >80 had an estimated 3-year OS of 49.3%, compared with 30.2% for KPS ≤80. Biallelic TP53 was associated with inferior survival (HR 4.05, 95% CI 1.76–9.32; p=0.001) (figure 1b), reaching statistical significance only in the MDS subgroup. A low blast count at diagnosis was associated with improved survival (HR 0.50, 95% CI 0.29–0.88; p=0.02). No clear associations were observed for age, HCT-CI, donor type, conditioning intensity or ATG. NRM did not differ significantly between MDS and AML (figure 1c). ALLOGENEIC HSCT FOR TP53-ABERRANT MYELOID NEOPLASMS: REAL-WORLD... - Myhre A - EHA-6995 - Jun 13 2026

We need influential medical experts to be active here on X. We can help by providing good medical information and updates for patients and colleagues. We can network. We can counter misinformation. Clarify complex questions. Share accomplishments and publications. And more. I learn every day. Although X has is not the same as the amazing platform Twitter used to be, it’s still the Number one social media platform for medicine. I’m happy to be here.

Clinical trials: Easy to criticize. Hard to do.

Florida Man doesn’t ask for permission. He just straps on a jet-propelled hoverboard, hooks up his dog to a jet ski, and goes for a Sunday cruise like it’s completely normal. This is why the rest of the country will never understand us. Peak Florida. Never change.

🇯🇵A Japanese developer built an app that puts a fat cat on your screen and forces you to take a break Silicon Valley spent billions on wellness platforms, mindfulness subscriptions, and digital detox retreats A guy in Japan said: fat cat, problem solved

Congratulations @Ernesto55788765 @edwardziga and team for ground breaking work for patients with #sicklecell disease. Phase 1/2 trial of risto-cel in patients with SCD led to rapid robust increase HbF,reduced HbS & no VOc @MayoClinic @MayoCancerCare @MKD_BMT @VamsiVelcheti

A new study evaluating Mayo’s Cancer CARE Beyond Walls program highlights how home-based chemotherapy can reduce the burden of cancer treatment while improving patients’ quality of life. catalyst.nejm.org/doi/full/1…

CONGRESS | #EBMT26 | PRESENTATION A Samer Al-Homsi presents interim results from the phase I-IIb ABC trial, evaluating PTCy dose reduction in patients receiving calcineurin- and mTOR inhibitor-free #GvHD prophylaxis with PTCy bortezomib abatacept (N = 60). PTCy dose was reduced from 50 mg/kg to 37.5 mg/kg. Reduced-dose vs full-dose PTCy was associated with faster neutrophil and platelet engraftment (15 vs 17 days; p = 0.004 and 22 vs 25.5 days; p = 0.04, respectively). No primary or secondary graft failure occurred. There were no differences in CD3 , CD4 or CD8 cell recovery between the two PTCy groups. By Day 180, the estimated cumulative incidences of Grade II-IV #aGvHD were 4.0% with full-dose PTCy and 11.8% with reduced-dose PTCy (p = 0.29). The 1-year estimated cumulative incidences of moderate and severe #cGvHD were 12% and 9.5% with full- and reduced-dose PTCy, respectively (p = 0.87). At 1 year, OS and GRFS were 91.3% and 70.9%, respectively. Follow our live feed for more updates: bit.ly/4lyVG9v Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #GvHDsm #MedNews #MedEd @TheEBMT @ASamerAlHomsi1 @ZuckerSoM

Cancer CARE (Connected Access and Remote Expertise) Beyond Walls — Safety, Feasibility, and Patient Experience of Home-Based Chemotherapy catalyst.nejm.org/doi/full/1… @RDroncaDr @CherylWillmanMD @KentThielen @Jcj84Jeremy @DoctorQMd @MayoClinic @MayoCancerCare

We grieve the untimely and heartbreaking loss of Dr. Sanjeet Grewal — a beloved husband, father, son, friend and an exceptionally gifted stereotactic and functional neurosurgeon. Read more: bit.ly/3ZrhQjJ

📣🚨Announcing the: ⭐️ 35th ANNUAL @MayoCancerCare Florida #Hematology/#Oncology Reviews at Amelia Island #RitzCarlton, I’m honored to co-lead from Jul 30 to Aug 1, 2026. ✅Comprehensive #CME #Practical (in-person & virtual) Conference, with AMAZING speakers from @MayoClinic & other GREAT centers. Join us👇🏼 ce.mayo.edu/hematology-and-o…

Come to the Plasma Cell Disorder Working committee this afternoon #Tandem2026 @CIBMTR  to vote on proposals! @ZanwarSaurabh @nadineabdal Ken Lim propose to examine comparative effectiveness of early vs late #CART in #mmsm 🧬📊@MayoCancerCare
 #medtwitter

Join our community here: roon.com If you’re an international physician/non-physician healthcare provider, join the waitlist here: airtable.com/appzPcoBRgsmUX2…

MN, AZ & FL @MayoClinic teams fuel up before a jam-packed day #tandem2026 @CIBMTR @ASTCT @MayoCancerCare @khera_nandita @hemant_murthy @MadihaIqbal13 @jonaspaludo @nadineabdal

“Nothing in this world can take the place of persistence. Talent will not; nothing is more common than unsuccessful men with talent. Genius will not; unrewarded genius is almost a proverb. Education will not; the world is full of educated derelicts. Persistence and determination alone are omnipotent. The slogan 'Press On!' has solved and always will solve the problems of the human race.” — President Calvin Coolidge

Every strong community starts with intentional builders. This week, we’re welcoming an impressive group of founding physicians to Roon. They bring expertise across research, education, and systems improvement, along with a shared commitment to thoughtful, evidence-based practice. By showing up early, they’re helping set the standard for the conversations and collaboration that will define our community going forward. We’re excited to be building Roon with them. If you’re a U.S.-based physician, we’d love for you to join the community. Links below.

Great to be at Mayo Clinic in Jacksonville with First Lady @CaseyDeSantis today to announce the launch of the only carbon ion therapy program in the Western Hemisphere—a major milestone for cancer care in Florida and nationwide. Our administration is committed to fighting cancer by making targeted investments in innovative therapies that have the potential to save lives. During my time as governor, we’ve increased funding for cancer research and treatment programs by more than 114 percent. The Casey DeSantis Cancer Research Program has strengthened Florida’s position as a national leader in cancer research and innovation. We’re proud that Mayo Clinic chose Florida as the home for this groundbreaking initiative, and we look forward to seeing how these cutting-edge therapies give hope to patients fighting some of the most aggressive and treatment-resistant cancers.

Mayo Clinic’s doctors and researchers are on the front lines of Florida’s fight against cancer. Today, we were happy to announce that Mayo Clinic in Jacksonville will be launching the first carbon ion therapy program in America. Carbon ion therapy, one of the most advanced forms of radiation treatment in the world, is designed to attack some of the most aggressive and treatment-resistant cancers. This cutting-edge treatment has the potential to save lives and give hope to those who need it most. Proton therapy will also be available in the same facility, allowing specialists to treat tumors with a higher degree of precision. While carbon ion therapy was originally discovered in the United States decades ago, it has only been available at a limited number of centers in Asia and Europe until now. Soon, cancer patients will have access to therapies that previously required traveling across the world, right here in Florida.